Targeting Glioma Initiating Cells With A Combined Therapy Of Cannabinoids And Temozolomide.

Targeting Glioma Initiating Cells With A Combined Therapy Of Cannabinoids And Temozolomide. Biochem Pharmacol. 2018 Sep 06;: Authors: López-Valero I, Sáiz-Ladera C, Torres S, Hernández Tiedra S, García-Taboada E, Rodríguez-Fornés F, Barba M, de León DD, Salvador-Tormo N, Guzmán M, Sepúlveda JM, Sánchez P, Lorente M, Velasco G Abstract Glioblastoma multiforme (GBM) is the most frequent and aggressive type of brain tumor due, at least in part, to its poor response to current anticancer treatments. These features could be explained, at least partially, by the presence within the tumor mass of a small population of cells termed Glioma Initiating Cells (GICs) that has been proposed to be responsible for the relapses occurring in this disease. Thus, the development of novel therapeutic approaches (and specifically those targeting the population of GICs) is urgently needed to improve the survival of the patients suffering this devastating disease. Previous observations by our group and others have shown that Δ9-Tetrahydrocannabinol (THC, the main active ingredient of marijuana) and other cannabinoids including cannabidiol (CBD) exert antitumoral actions in several animal models of cancer, including gliomas. We also found that the administration of THC (or of THC + CBD at a 1:1 ratio) in combination with temozolomide, the benchmark agent for the treatment of GBM, synergistically reduces the growth of glioma xenografts. In this wor...
Source: Biochemical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Biochem Pharmacol Source Type: research